오피오이드 사용 장애 시장 규모, 점유율, 동향 분석 보고서 : 약물별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Opioid Use Disorder Market Size, Share & Trends Analysis Report By Drug (Naltrexone, Buprenorphine, Methadone), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

오피오이드 사용 장애 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 오피오이드 사용 장애 시장 규모는 2030년까지 102억 4,000만 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 연평균 11.15%의 CAGR을 나타낼 것으로 예상됩니다.

오피오이드 확산의 증가와 위기 퇴치를 위한 정부 이니셔티브의 증가는 시장 성장을 촉진할 것으로 보입니다. 또한, 2018년 미국에서는 15세 이상의 약 290만 명이 이 장애를 앓고 있으며, 2016년 미국 약물 사용 및 건강 전국 조사(NSDUH)에 따르면, 전년도에 약 1,150만 명이 처방약인 오피오이드를 남용했으며, 200만 명이 처방약 중독에 빠졌다고 합니다. 를 남용했고, 200만 명 이상이 처방약 중독에 시달렸습니다.

CDC에 따르면 매일 약 130명의 미국인이 오피오이드 과다 복용으로 사망하고 있으며, 미국 정부는 이를 공중보건 비상사태로 규정하고 있습니다. 중독을 극복하고자 하는 환자들에게 약물 보조 치료(MAT)를 준수하면 금단 증상을 줄이고 사망 위험을 절반으로 줄일 수 있습니다. 미국 FDA가 승인한 MAT는 부프레노르핀, 메타돈, 날트렉손의 세 가지가 있습니다. 부프레노르핀을 매일 경구 투여하는 것이 표준 치료법입니다.

오피오이드 위기에 대처하기 위해 최근 몇 가지 조치가 취해지고 있습니다. 예를 들어, 2016년에는 만성 통증에 대한 오피오이드 처방을 위한 CDC 임상진료지침이 발표되었고, 2015년에는 표준 치료를 개선하기 위한 새로운 미국중독학회(ASAM) 전국진료지침이 채택되었습니다. 또한 2016년 미국 FDA는 오남용 억제 오피오이드에 대한 규제를 전면적으로 재검토하고, 안전성 표시를 강화하며, 사용의 위험-편익 패러다임을 재검토할 계획을 발표했습니다.

오피오이드 사용 장애 시장 보고서 하이라이트

• 부프레노르핀은 오피오이드 부분 작용제로서 효과적인 이중 작용으로 시장을 선도하고 있으며, 2024년 세계 매출의 59.58%를 차지했습니다.
• 주사제 부문은 2024년 세계 매출의 59.26%를 차지하며 시장을 주도했습니다. 비비트롤(날트렉손)이나 서방형 주사제(부프레노르핀)와 같은 서방형 주사제는 장시간 안정적인 약물전달을 제공하고, 복약 순응도를 개선하며, 재발 위험을 감소시킵니다.
• 병원 약국은 복잡하고 심각한 환자 관리에 필수적인 역할을 담당하고 있기 때문에 2024년 시장 점유율 47.90%로 시장을 독점했습니다.
• 북미 오피오이드 사용 장애 시장은 몇 가지 주요 요인으로 인해 2024년 68.98%의 점유율을 차지했습니다. 이 지역은 OUD 유병률이 가장 높은 지역으로, 치료 솔루션에 대한 큰 수요를 주도하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 오피오이드 사용 장애 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• 오피오이드 사용 장애 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
• 가격 분석
• 파이프라인 분석
• 행동치료에 관한 정성 분석

제4장 오피오이드 사용 장애 시장 분석, 약제별

• 의약품 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 약물 전망에 의한 세계의 오피오이드 사용 장애 시장
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
  • 부프레노르핀
  • 메사돈
  • 날트렉손
  • 기타

제5장 오피오이드 사용 장애 시장 분석, 투여 경로별

• 오피오이드 사용 장애 : 투여 경로 변동 분석
• 오피오이드 사용 장애 시장 분석, 투여 경로별 시장
  • 경구 투여
  • 주사제 투여
  • 기타

제6장 오피오이드 사용 장애 시장 분석, 유통 채널별

• 오피오이드 사용 장애 : 유통 채널 변동 분석
• 오피오이드 사용 장애 시장 분석, 유통 채널 시장별
  • 병원 약국
  • 소매 약국
  • 기타

제7장 오피오이드 사용 장애 시장 : 약제별, 투여 경로별, 유통 채널별 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 동향 분석, 2018년에서 2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • 주요 판매대리점 및 채널 파트너 리스트
  • Key customers
  • Key company market share analysis, 2024
  • Indivior PLC
  • Teva Pharmaceutical Industries, Ltd.
  • Pfizer, Inc.
  • BioDelivery Sciences International, Inc.(a part of Collegium Pharmaceutical, Inc.)
  • Genentech, Inc.(Roche)
  • Alkermes.
  • Orexo US Inc.(subsidiary of Orexo AB)
  • Titan Pharmaceuticals, Inc.
  • Omeros Corporation
  • Camurus AB
  • Hikma Pharmaceuticals PLC

ksm

영문 목차

영문목차

Opioid Use Disorder Market Growth & Trends:

The global opioid use disorder market size is expected to reach USD 10.24 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 11.15% from 2025 to 2030. Rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.

According to the CDC, around 130 Americans die every day due to the opioid overdose and the U.S. government has designated this as a public health emergency.For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.

To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.

Opioid Use Disorder Market Report Highlights:

• Buprenorphine led the market and accounted for 59.58% of the global revenue in 2024 due to its effective dual action as a partial opioid agonist, which helps alleviate withdrawal symptoms and cravings while minimizing euphoria and misuse risk.
• The injectable segment dominated the market and accounted for 59.26% of the global revenue in 2024. Extended release injectables, like Vivitrol (naltrexone) and Sublocade (buprenorphine), offer prolonged, steady drug delivery, improving adherence and reducing the risk of relapse.
• Hospital pharmacies dominated the market with a market share of 47.90% in 2024 due to their integral role in managing complex and severe cases.
• North America opioid use disorder market accounted for 68.98% share in 2024 due to several key factors. The region has the highest prevalence of OUD, which drives significant demand for treatment solutions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary Distribution Channels
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Distribution Channels
• 1.9. List of Primary Distribution Channels
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug
  • 2.2.2. Route of Administration
  • 2.2.3. Distribution Channel
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Opioid Use Disorder Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising opioid epidemic
    • 3.2.1.2. Growing government initiatives to combat the crisis
    • 3.2.1.3. Growing awareness of opioid use disorder (OUD)
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Adverse effects associated to drug used for opioid treatment
    • 3.2.2.2. Complex reimbursement structure
• 3.3. Opioid Use Disorder Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis
• 3.5. Pipeline Analysis
• 3.6. Qualitative analysis about Behavioral Therapies

Chapter 4. Opioid Use Disorder Market Analysis, by Drug, 2018-2030 (USD Million)

• 4.1. Drug Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Opioid Use Disorder Market by Drug Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Buprenorphine
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Belbuca
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Suboxone
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Zubsolv
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.5. Others
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Methadone
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Naltrexone
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Opioid Use Disorder Market Analysis, by Route of Administration, 2018-2030 (USD Million)

• 5.1. Opioid Use Disorder: Route of Administration Movement Analysis
• 5.2. Opioid Use Disorder Market Analysis, by Route of Administration Market (USD Million)
  • 5.2.1. Oral Administration
    • 5.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 5.2.2. Injectable Administration
    • 5.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 5.2.3. Others
    • 5.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

Chapter 6. Opioid Use Disorder Market Analysis, by Distribution Channel, 2018-2030 (USD Million)

• 6.1. Opioid Use Disorder: Distribution Channel Movement Analysis
• 6.2. Opioid Use Disorder Market Analysis, by Distribution Channel Market (USD Million)
  • 6.2.1. Hospital Pharmacies
    • 6.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 6.2.2. Retail Pharmacies
    • 6.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 6.2.3. Others
    • 6.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

Chapter 7. Opioid Use Disorder Market: Regional Estimates and Trend Analysis by Drug, by Route of Administration, by Distribution Channel

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Indivior PLC
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Drug benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Teva Pharmaceutical Industries, Ltd.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Drug benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Pfizer, Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Drug benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. BioDelivery Sciences International, Inc. (a part of Collegium Pharmaceutical, Inc.)
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Drug benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Genentech, Inc. (Roche)
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Drug benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Alkermes.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Drug benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Orexo US Inc. (subsidiary of Orexo AB)
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Drug benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Titan Pharmaceuticals, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Drug benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Omeros Corporation
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Drug benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Camurus AB
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Drug benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Hikma Pharmaceuticals PLC
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Drug benchmarking
    • 8.3.14.4. Strategic initiatives

관련자료